(Q57975538)

English

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer

article

In more languages

Statements

scholarly article

0 references

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Jason Konner

8

0 references

11

object named as

Dennis S. Chi

0 references

Carol Aghajanian

10

object named as

Carol Aghajanian

0 references

author name string

Joyce N. Barlin

1

0 references

Fanny Dao

2

0 references

Nadim Bou Zgheib

3

0 references

Sarah E. Ferguson

4

0 references

Paul J. Sabbatini

5

0 references

Martee L. Hensley

6

0 references

Katherine M. Bell-McGuinn

7

0 references

William P. Tew

9

0 references

language of work or name

0 references

publication date

June 2012

0 references

Gynecologic Oncology

0 references

125

0 references

3

0 references

621-624

0 references

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.027

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.027

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.027

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.027

7 January 2021

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.027

7 January 2021

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.027

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.027

7 January 2021

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.027

7 January 2021

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.03.027

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.03.027

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57975538&oldid=2046271863"